Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
98.20    -0.80 (-0.81%)
Bid:
98.20
Ask:
99.10
Spread: 0.90 (0.916%)
Market Cap: £597.25m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
12th May 20211:18 pmRNSDirector/PDMR Shareholding
11th May 202112:05 pmRNSAchilles reports Q1 financial results
7th May 20217:00 amRNSGyroscope Therapeutics update on proposed IPO
6th May 202112:05 pmRNSAutolus reports Q1 2021 Financial Results
4th May 20217:00 amRNSUpdate on Gyroscope proposed IPO in the US
19th Apr 202112:05 pmRNSAutolus appoints non-executive Chair
19th Apr 20217:00 amRNSGyroscope files registration statement
6th Apr 20214:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSFreeline Reports Financial Results
31st Mar 20217:00 amRNSAchilles update on IPO
30th Mar 202112:04 pmRNSDirector/PDMR Shareholding
26th Mar 20217:06 amRNSGyroscope announces additional financing plans
26th Mar 20217:00 amRNSSyncona cornerstones $148m Series C in Gyroscope
25th Mar 202111:13 amRNSUpdate on Achilles’ proposed IPO
4th Mar 202112:10 pmRNSAutolus Reports Full Year 2020 Financial Results
2nd Mar 20217:00 amRNSAchilles files registration statement
12th Feb 20213:49 pmRNSGyroscope Announces Positive Interim Data
11th Feb 20217:00 amRNSNew commitment to Quell in largest ever Series A
11th Feb 20217:00 amRNSQuarterly and Business Update
10th Feb 20217:00 amRNSAutolus announces pricing of public offering
8th Feb 202112:09 pmRNSFreeline Updates Clinical Development Plan
5th Feb 20217:00 amRNSAchilles announces additional financing plans
5th Feb 20217:00 amRNSAchilles data and safety committee review
6th Jan 20217:00 amRNSAutolus Business Outlook
21st Dec 20207:00 amRNSVirginia Holmes Appointed Non-Executive Director
14th Dec 202012:05 pmRNSFreeline reports updated clinical data
7th Dec 20205:05 pmRNSAutolus presents additional data on AUTO3
7th Dec 20207:05 amRNSAutolus presents additional data on AUTO1
27th Nov 20204:35 pmRNSPrice Monitoring Extension
19th Nov 20207:00 amRNSSyncona founds Purespring with a £45m Series A
19th Nov 20207:00 amRNSHalf-year Report
5th Nov 202012:11 pmRNSAutolus reports Q3 2020 Financial Results
3rd Nov 20208:30 amRNSNotice of Results
2nd Nov 20207:00 amRNSDirectorate Change
30th Oct 20207:00 amRNSFreeline H1 Results and Business Highlights
18th Sep 20208:10 amRNSAutolus presents additional data on AUTO3
14th Sep 20201:05 pmRNSSyncona expands cell therapy portfolio
7th Sep 202012:07 pmRNSSecond Price Monitoring Extn
7th Sep 202012:02 pmRNSPrice Monitoring Extension
10th Aug 20207:00 amRNSQuarterly Update
7th Aug 20207:00 amRNSFreeline update on IPO
6th Aug 202012:10 pmRNSAutolus reports Q2 2020 Financial Results
3rd Aug 202011:30 amRNSUpdate on Freeline proposed IPO in the U.S.
28th Jul 202012:00 pmRNSResult of AGM
20th Jul 20207:00 amRNSFreeline files registration statement
13th Jul 20204:51 pmRNSFreeline publishes further data for FLT180a
9th Jul 20201:00 pmRNSIssue of shares pursuant to Incentive Scheme
30th Jun 20207:00 amRNSFreeline announces additional financing plans
30th Jun 20207:00 amRNSFreeline expands Series C financing to $120million
25th Jun 202012:38 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.